DUBLIN--(BUSINESS WIRE)--The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering. This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward? What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer? Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity?
If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitorIDO inhibitor? Based on published Phase II data, how do the experts view the results so far for BC-819 with BCGBCG in patients with NMIBC? Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?
How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent? If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC? What are KOLs' opinions on the supply shortages previously reported for the BCGBCG vaccine and are they being addressed? For more information about this newsletter visit https://www.researchandmarkets.com/r/9ke1kl